Fuel Up on Krispy Krunchy Chicken's $5.99 Inflation-Buster Meal
Customers can now enjoy great-tasting, mildly Cajun-spiced chicken across each of the 48 contiguous United States. The Your Choice Combo offers guests the option of 3-piece bone-in chicken, 3-piece jumbo tenders, 6-piece chicken nuggets or the Cajun Chicken Sandwich, with each meal accompanied by crispy potato wedges. The price is $5.99 whichever combo is chosen, though pricing and participation may vary and the price is not available for online orders.
But that's not all! Krispy Krunchy Chicken is elevating the flavor experience with a lineup of reformulated and redesigned dipping sauces designed to take the experience to the next level. Through extensive research, Krispy Krunchy has made its sauces even more craveable. Available to stores now, the new sauce lineup is expected to be in most locations by August 1 and includes:
New! Signature Krunch Sauce: A bold remix of classic comeback sauce that's creamy, tangy, peppery, and unapologetically craveable.
Ranch: Creamy and zesty, this classic ranch sauce is herb-kissed and perfect for dipping, drizzling and dunking.
Buffalo: The intersection of fiery and tangy – this sauce packs a punch with a smooth finish that keeps things interesting.
Honey Mustard: Sweet meets tangy in this smooth and perfectly balanced fan favorite.
Barbeque: A savory sauce that's both rich and smoky with just enough sweetness.
Sweet & Sour: This one's got range! It's tangy, zesty and has just the right amount of sass.
"We have always believed that our operators and their customers deserve more – more quality, more value, more craveable options. While no one is immune to inflation, Krispy Krunchy is consistently serving up flavorful and highly craveable chicken at a fantastic value with the convenience consumers need," said Jim Norberg, CEO of Krispy Krunchy Chicken. 'We believe our all-white breast meat chicken nuggets, Cajun chicken sandwich and hand-breaded jumbo tenders and bone-in chicken are the best in the market and we're pricing this combo so that everyone can taste for themselves.'
In addition to these fan favorites, Krispy Krunchy ® also offers wings, an assortment of sides, honey biscuits, and family meals. Pick up at your nearest location or order delivery through DoorDash, Grubhub, Postmates, or Uber Eats (where available). For more information about Krispy Krunchy Chicken ®, visit www.krispykrunchy.com or follow the brand on Facebook and Instagram.
About Krispy Krunchy Chicken ®
Krispy Krunchy Chicken ® (KKC) operates nearly 3,400 quick-serve locations in all 48 of the contiguous United States, selling over a million pounds of chicken every week. The company provides foodservice solutions for convenience stores, truck stops, universities, casinos and more across the U.S., including in Fenway Park, where it is the 'Official Fried Chicken of the Boston Red Sox." Founded in Louisiana in 1989, the store-in-store concept allows licensees to serve hand-breaded, mildly Cajun-spiced fried chicken and all-white meat jumbo tenders to its guests to increase their in-store profitability and drive frequency. The full menu also includes a variety of sides and the brand's trademark honey biscuits. To learn more about partnering with Krispy Krunchy Chicken ®, visit http://krispykrunchy.com/partnering.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
15 hours ago
- Business Insider
MRNA Earnings: Moderna Stock Slumps 10% on Lower Covid Vaccine Demand
Shares in drug giant Moderna (MRNA) plummeted nearly 10% today after it reported a drop in Q2 sales. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The company reported earnings for the period of -$2.13, beating expectations of -$3.03 but also recorded a 41.1% drop in year-over-year sales to $142 million. However, that still beat forecasts of $128.3 million. Sentiment Hit Investor sentiment was also hit by the company dropping its revenue guidance for the full year to $1.85 billion at the midpoint from $2 billion, a 7.5% decrease. It blamed the 'timing of shipments.' The decline was primarily driven by lower Spikevax COVID vaccine sales, which totaled $114 million in the quarter. Moderna said demand is expected to be concentrated in the second half of the year, aligning with the fall and winter seasons as the vaccine continues to transition into a seasonal respiratory product. It also reported 'negligible' RSV vaccine mRESVIA® sales in the second quarter of 2025. The figures continue Moderna's difficult year in comparison with its peers – see below. 'In the last three months, we advanced our pipeline with positive Phase 3 flu vaccine efficacy data and expanded our commercial portfolio with three new U.S. FDA approvals to drive future sales growth,' said Stéphane Bancel, Chief Executive Officer of Moderna. 'Looking forward, we have important catalysts over the next six months across our infectious disease and oncology programs that will help us deliver on the promise of our mRNA platform for patients.' Future Hopes This includes Intismeran autogene, a personalized cancer therapy which is being developed in collaboration with Merck (MRK). This includes two non-small cell lung cancer Phase 3 studies and Phase 2 studies for high-risk muscle invasive and high-risk non-muscle invasive bladder cancer. Cost of sales for 2025 is expected to be approximately $1.2 billion. Full-year 2025 research and development expenses are anticipated to be $3.6 to $3.8 billion, lowered from previous expectations of approximately $4.1 billion. Year-end cash and investments for 2025 are projected to be approximately $6 billion. Recently, Moderna announced an organizational restructuring that will reduce its global workforce by approximately 10%. The company anticipates a total headcount of less than 5,000 by the end of the year. Better news came today for the group after Pfizer (PFE) and its German partner BioNTech (BNTX) lost their bid to overturn a ruling that their COVID-19 vaccine infringed one of Moderna's patents at London's Court of Appeal.
Business Wire
20 hours ago
- Business Wire
Align Technology President and CEO Joe Hogan Personally Purchases $1 Million of Align's Common Stock
TEMPE, Ariz.--(BUSINESS WIRE)--Align Technology, Inc. ('Align') (Nasdaq: ALGN) a leading global medical device company that designs, manufactures, and sells the Invisalign ® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that Joe Hogan, Align Technology president and CEO, has personally purchased approximately $1 million of Align's common stock. Since his last sale of Align common stock in 2021, Mr. Hogan has purchased approximately $8 million of Align common stock 1. 'This purchase reflects my continuing confidence in the long-term value of Align and our commitment to increasing shareholder value by balancing investments to drive growth and continuing to invest with discipline in the areas that will define our future,' said Joe Hogan, president and CEO. 'We are excited about our next-generation technologies and treatment platforms that meet today's patient expectations for fast, effective, and personalized treatment while also providing value and growth opportunities for our doctor customers. We believe that these innovations are not only improving outcomes in Invisalign practices but also expanding our addressable market and strengthening our competitive differentiation.' Continued Hogan, 'While we believe that the macroeconomic uncertainty will likely persist into the near future, we are confident in our ability to adapt and lead. Our long-term strategic initiatives and opportunities remain intact, as does our commitment to focused execution on transforming treatment for doctors and patients.' 1 Valued based on the purchase price of Align common stock at the time of each purchase. About Align Technology Align Technology designs and manufactures the Invisalign ® System, the most advanced clear aligner system in the world, iTero™ intraoral scanners and services, and exocad™ CAD/CAM software. These technology building blocks enable enhanced digital orthodontic and restorative workflows to improve patient outcomes and practice efficiencies for over 286.4 thousand doctor customers and are key to accessing Align's 600 million consumer market opportunity worldwide. Over the past 28 years, Align has helped doctors treat over 20.8 million patients with the Invisalign System and is driving the evolution in digital dentistry through the Align™ Digital Platform, our integrated suite of unique, proprietary technologies and services delivered as a seamless, end-to-end solution for patients and consumers, orthodontists and GP dentists, and lab/partners. Visit for more information. For additional information about the Invisalign System or to find an Invisalign doctor in your area, please visit For additional information about the iTero digital scanning system, please visit For additional information about exocad dental CAD/CAM offerings and a list of exocad reseller partners, please visit Invisalign, iTero, exocad, Align, Align Digital Platform, and iTero Lumina are trademarks of Align Technology, Inc.
Business Wire
a day ago
- Business Wire
KORU Medical Systems Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
MAHWAH, N.J.--(BUSINESS WIRE)-- KORU Medical Systems, Inc. (NASDAQ: KRMD) ('KORU Medical' or the 'Company'), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced inducement equity awards to Adam Kalbermatten, Chief Commercial Officer, pursuant to his previously announced employment agreement with the Company dated as of June 30, 2025. Mr. Kalbermatten was granted nonqualified stock options on August 1, 2025 to purchase 600,000 shares of the Company's common stock at an exercise price of $3.44 per share. In addition, on July 28, 2025, his start date, Mr. Kalbermatten received 300,000 restricted shares of the Company's common stock. Each of these awards are subject to vesting 25% on each anniversary of their grant date, subject to accelerated vesting and the other terms and conditions of the respective award agreements entered into between Mr. Kalbermatten and the Company. The Compensation Committee of the Company's Board of Directors approved the awards as an inducement material to Mr. Kalbermatten's employment in accordance with Nasdaq Listing Rule 5635(c)(4). About KORU Medical Systems KORU Medical Systems develops, manufactures, and commercializes innovative and patient-centric large volume subcutaneous infusion solutions that improve quality of life for patients around the world. The Freedom Syringe Infusion System (the 'Freedom System') currently includes the Freedom60® and FreedomEdge® Syringe Infusion Drivers, Precision Flow Rate Tubing™ and HigH-Flo Subcutaneous Safety Needle Sets™. The Freedom System, which received its first FDA clearance in 1994, is used for self-administration in the home by the patient and/or delivery in an ambulatory infusion center by a healthcare professional. Through its Pharma Services and Clinical Trials business, KORU Medical provides products for use by biopharmaceutical companies in feasibility/clinical trials during the drug development process and, as needed, is capable of customizing the Freedom System for clinical and commercial use across multiple drug categories. For more information, please visit
